【摘要】 目的评价国产坎地沙坦酯胶囊治疗轻中度原发性高血压的疗效和安全性。方法80例轻、中度原发性高血压患者随机接受坎地沙坦酯胶囊4mg或缬沙坦胶囊80mg治疗,每日一次。4周后根据血压情况决定是否剂量加倍。总疗程8周。结果坎地沙坦酯组治疗前的SBP/DBP为(158.1±12.1)/(98.0±5.9)mmHg,治疗后的SBP/DBP为(141.2±10.9)/(86.6±6.2)mmHg,血压下降幅度为(16.9±9.2)/(11.4±6.5)mmHg,缬沙坦组治疗前的SBP/DBP为(159.8±13.4)/(100.1±5.0)mmHg,治疗后的SBP/DBP为(144.1±11.6)/(86.7±5.5)mmHg,血压下降幅度为(15.7±10.8)/(13.4±7.0)mmHg。两组治疗后血压降低幅度均有统计学意义,而两组间无差异。治疗前后心率无明显变化。坎地沙坦酯和缬沙坦降压显效率分别为60.0%和64.1%,总有效率分别为85.0%和87.2%,组间无差别。不良事件少。结论国产坎地沙坦酯胶囊治疗轻、中度原发性高血压疗效确切,耐受性好,不良反应少。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of domestic produced candesartan cilexetil in patients with mild-to-moderate essential hypertension. Methods Eighty patients were randomly assigned to receive candesartan cilexetil(4mg/d)or valsartan(80mg/d). The dosages were titrated to double the doses when DBP was sustained≥90mmHg or the magnitude of reduction was less than 10mmHg. Results Systolic blood pressure (SBP)/diastolic blood pressure(DBP) decreased significantly from(158.1+12.1)/(98.0±5.9)mmHg to (141.2±10.9)/(86.6±6.2)mmHg in candesartan cilexetil group and from (159.8±13.4)/(100.1±5.0)mmHg to(144.1±11.6)/(86.7±5.5)mmHg in valsartan group. The responsive rate was 85.0% in candesartan cilexetil group, and 87.2% in valsartan group. No change in heart rate was found. Adverse reactions were non-significant. Conclusion Domestic produced candesartan ciexetil is effective and well tolerated in patients with mild-to-moderate essential hypertension, and without significant adverse reaction.更多还原